Peter Dritschilo
Präsident bei SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
Vermögen: 2 617 $ am 30.04.2024
Profil
Peter Dritschilo currently works at Shuttle Pharmaceuticals, Inc., as President & Chief Operating Officer from 2012 and Shuttle Pharmaceuticals Holdings, Inc., as President & Chief Operating Officer.
Mr. Dritschilo received his undergraduate degree from Georgetown University and Masters Business Admin degree from The GW School of Business.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 21.03.2024 | 6 560 ( 0,04% ) | 2 617 $ | 30.04.2024 |
Aktive Positionen von Peter Dritschilo
| Unternehmen | Position | Beginn |
|---|---|---|
| SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | Präsident | 18.12.2012 |
Shuttle Pharmaceuticals, Inc.
 Shuttle Pharmaceuticals, Inc. BiotechnologyHealth Technology Shuttle Pharmaceuticals, Inc. operates as a pharmaceutical company which engages in the development and commercialization of drugs. It focuses on innovative drugs for sensitizing cancers to and protecting normal tissue from the effects of radiation therapy. The firm's products include novel HDAC inhibitor cancer drug candidates. The company was founded by Anatoly Dritschilo, Milton Brown, and Mira Jung in December 2012 and is headquartered in Rockville, MD. | Präsident | 01.12.2012 |
Ausbildung von Peter Dritschilo
| Georgetown University | Undergraduate Degree |
| The GW School of Business | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SHUTTLE PHARMACEUTICALS HOLDINGS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Shuttle Pharmaceuticals, Inc.
Shuttle Pharmaceuticals, Inc. BiotechnologyHealth Technology Shuttle Pharmaceuticals, Inc. operates as a pharmaceutical company which engages in the development and commercialization of drugs. It focuses on innovative drugs for sensitizing cancers to and protecting normal tissue from the effects of radiation therapy. The firm's products include novel HDAC inhibitor cancer drug candidates. The company was founded by Anatoly Dritschilo, Milton Brown, and Mira Jung in December 2012 and is headquartered in Rockville, MD. | Health Technology |
